Form 4 for DMAA Drugs Made In America Acquisition Corp.

Accepted 2025-02-18 00:00:00 ET · period of report 2025-02-18 · accession 0001213900-25-015020 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2025-02-18	2025-02-18	DMAA	Drugs Made In America Acquisition LLC	10%	P - Purchase	—	+30.0K	4.19M	+0.7%	—
D	2025-02-18	2025-02-18	DMAA	Drugs Made In America Acquisition LLC	10%	P - Purchase	—	+30.0K	430.0K	+8%	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary shares	2025-02-18	P	A	30,000	—	4,188,780	D	—	—	(F1) Reflects the 30,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000.
2	Derivative	Rights to receive ordinary shares	2025-02-18	P	A	30,000	—	430,000	D	— · — to —	30,000 Ordinary shares	(F1) Reflects the 30,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. (F2) The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.